| Ytd | -26.60% | |
| 1y | 63.10% |
| Open | 36.64 | Prev Close | 36.99 | Low | 36.12 | High | 37.52 | Mkt Cap | 2.67B |
| Vol | 1.10M | Avg Vol | 1.62M | EPS | -5.54 | P/E | -6.71 | Forward P/E | -10.88 |
| Beta | 0.92 | Short Ratio | 7.83 | Inst. Own | 110.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 37.15 | 200-d Avg | 38.78 | 1yr Est | 81.79 |
VERA News
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approv
BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today ann
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commer
TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the p
Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises th
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the
US stock futures lower with Dow down 500 points. Kura Sushi shares drop after reporting worse-than-e
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Tr
B of A Securities analyst Dina Ramadane maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and
Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease dr
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and
Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. F
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today ann
You can argue about almost every line in a NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) earnings rel
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Po
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephr
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today anno
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BL
BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotech
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today an
JPMorgan Chase and Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) by 73.5%
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today an
During Monday's trading, 1214 companies set new 52-week lows.